GlassScriptPhysician profile
Ahmad A Fora
NPI 1386875011
$15,877.24
in general payments reported to CMS, 2019-2025
82 companies · $5,457 in 2025
The $5,457 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $1,245 · 2021: $843 · 2022: $185 · 2023: $2,271 · 2024: $4,468 · 2025: $5,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $698 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,371.39 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $126.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,545.76 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,323.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $925.83 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Janssen Biotech, INC. | $866.56 | 2019-2025 | Tecvayli, Rybrevant, Erleada |
| Abbvie INC. | $859.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $715.45 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Pfizer INC. | $659.66 | 2019-2025 | |
| Celgene Corporation | $592.73 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Genentech USA, INC. | $552.78 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Glaxosmithkline, LLC. | $423.22 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Exelixis INC. | $409.70 | 2023-2025 | Cabometyx |
| Incyte Corporation | $389.74 | 2020-2025 | Jakafi, Monjuvi, Niktimvo |
| Astellas Pharma US INC | $388.12 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $266.78 | 2020-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $257.06 | 2019-2025 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $242.24 | 2020-2025 | |
| Lilly USA, LLC | $242.13 | 2019-2025 | Verzenio, Jaypirca |
| Octapharma USA, INC. | $230.44 | 2019-2024 | Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $224.20 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Karyopharm Therapeutics INC. | $219.89 | 2020-2024 | Xpovio |
| Eisai INC. | $205.87 | 2019-2025 | |
| Daiichi Sankyo INC. | $200.52 | 2020-2025 | Enhertu, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $186.43 | 2021-2025 | Libtayo |
| Taiho Oncology, INC. | $175.14 | 2024-2025 | |
| Emd Serono, INC. | $165.47 | 2019-2025 | Bavencio, Tepmetko |
| Beigene USA, INC. | $164.66 | 2020-2025 | Tevimbra, Brukinsa |
| Rigel Pharmaceuticals, INC. | $153.23 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beone Medicines USA, INC. | $147.47 | 2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $145.53 | 2024-2025 | Beleodaq, Ryzneuta |
| Amgen INC. | $138.88 | 2020-2023 | Vectibix, Xgeva, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.01 | 2019-2025 | Gilotrif |
| Coherus Oncology, INC. | $122.21 | 2024-2025 | Loqtorzi |
| Gilead Sciences, INC. | $116.17 | 2019-2025 | Trodelvy |
| Alnylam Pharmaceuticals INC. | $115.70 | 2024-2025 | Oxlumo |
| Genmab U.S., INC. | $112.59 | 2023-2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $109.57 | 2023-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $108.98 | 2020-2024 | |
| Agios Pharmaceuticals, INC. | $108.91 | 2020-2024 | Pyrukynd |
| Array Biopharma INC | $108.14 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Legend Biotech USA INC. | $104.54 | 2025 | Carvykti |
| Stemline Therapeutics INC. | $101.85 | 2024-2025 | Orserdu |
| Seagen INC. | $100.04 | 2019-2023 | Tukysa, Adcetris |
| Adc Therapeutics America, INC. | $92.51 | 2024-2025 | |
| Tempus Ai, INC | $89.51 | 2024-2025 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $78.74 | 2025 | |
| Apellis Pharmaceuticals, INC. | $77.47 | 2023-2024 | Empaveli |
| Tersera Therapeutics LLC | $70.55 | 2023-2024 | Zoladex |
| Sobi, INC | $64.71 | 2023-2024 | |
| Mirati Therapeutics, INC. | $62.84 | 2023-2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $57.63 | 2024-2025 | |
| Kite Pharma, INC. | $57.43 | 2020-2023 | Yescarta |
| Puma Biotechnology, INC. | $52.58 | 2021-2024 | |
| Blueprint Medicines Corporation | $51.06 | 2025 | Ayvakit |
| Spectrum Pharmaceuticals INC. | $50.32 | 2023-2025 | Rolvedon |
| Pharmacosmos Therapeutics INC. | $45.49 | 2024-2025 | Monoferric |
| Iovance Biotherapeutics, INC. | $41.02 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $39.84 | 2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $39.65 | 2019 | |
| Myovant Sciences INC. | $33.21 | 2021 | |
| Organon LLC | $32.74 | 2023 | Ontruzant |
| Secura Bio, INC. | $31.94 | 2020 | |
| Geron Corporation | $31.75 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $30.97 | 2023-2024 | Tazverik, Onivyde |
| Cycle Pharmaceuticals INC | $28.41 | 2025 | Phyrago |
| Novocure INC. | $25.02 | 2025 | Optune Lua (Novottf-200t) |
| Amneal Pharmaceuticals LLC | $23.93 | 2025 | Alymsys |
| Boston Scientific Corporation | $23.60 | 2020 | |
| Caris Mpi, INC. | $21.70 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $21.62 | 2024 | |
| Pharmaand Gmbh | $21.61 | 2025 | Rubraca |
| Clovis Oncology, INC. | $21.55 | 2020 | |
| Deciphera Pharmaceuticals INC. | $21.24 | 2025 | Qinlock, Romvimza |
| Azurity Pharmaceuticals, INC. | $20.79 | 2025 | Danziten |
| Fennec Pharmaceuticals, INC. | $20.06 | 2025 | Fyarro |
| Acceleron Pharma, INC. | $19.29 | 2020 | |
| Recordati_rare_diseases_inc. | $17.49 | 2023 | Sylvant |
| Epizyme, INC. | $17.39 | 2021 | |
| Syndax Pharmaceuticals, INC. | $17.01 | 2025 | |
| Morphosys, US INC. | $16.88 | 2021 | |
| Sirtex Medical INC | $16.68 | 2020 | |
| Tactile Systems Technology INC | $13.28 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
Kisqali $932Imbruvica $649Keytruda $562Opdivo $536Epkinly $505Reblozyl $427Enhertu $419Cabometyx $410Opdualag $363Tecvayli $261Rybrevant $227Erleada $220Pomalyst $218Elrexfio $218Jakafi $215Darzalex $209Adcetris $198Calquence $187Lonsurf $175Inqovi $175Lynparza $173Lenvima $168Tagrisso $162Akeega $162Brukinsa $153Rezlidhia $153Tavalisse $153Tukysa $153Jemperli $152Libtayo $142Scemblix $139Polivy $133Padcev $132Xtandi $131Balversa $128Carvykti $127Oxlumo $116Stivarga $115Vitrakvi $115Fruzaqla $113Lunsumio $112Tevimbra $112Phesgo $111Talvey $110Fotivda $110Zejula $109Mektovi $108Lorbrena $108Braftovi $108Venclexta $105Monjuvi $104Orserdu $102Beleodaq $99.42Verzenio $99.07Elahere $90.54Gavreto $86.98Ojjaara $85.74Sarclisa $82.55Xalkori $80.44Nubeqa $79.42Columvi $79.32Pylarify $78.74Zynlonta $78.47Empaveli $77.47Vyloy $72.75Jaypirca $71.69Udenyca $71.19Niktimvo $70.69Zoladex $70.55Krazati $62.84Tecentriq $61.72Trodelvy $60.61Xospata $60.34Ninlaro $59.39Ibrance $58.57Yonsa $57.63Gilotrif $56.40Talzenna $56.04Orgovyx $56.04Imfinzi $52.79Ayvakit $51.06Loqtorzi $51.02Fabhalta $50.59Rolvedon $50.32Ryzneuta $46.11Monoferric $45.49Cresemba $45.37Augtyro $45.15Welireg $44.13Amtagvi $41.02Pemazyre $40.17Besremi $39.84Zepzelca $39.71Rozlytrek $38.96Alecensa $38.96Bosulif $37.52Piqray $37.03Doptelet $35.05Xofigo $33.12Ontruzant $32.74
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Fora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.